Navigation Links
Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
Date:2/10/2012

shareholder value."

Tony Sedgwick holds 1,108,108 shares (0.19%) of the issued share capital in the Company.  No further disclosures are required under Rule 17 and Schedule 2(g) of the AIM Rules.

Notes for Editors

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. Silence offers one of the most comprehensive short interfering RNA (siRNA) therapeutic platforms available today based on a strong intellectual property portfolio and large clinical safety database. Silence's clinical siRNA product pipeline is one of the broadest in the industry. The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX™, DACC and DBTC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endothelium with a long duration of target mRNA and protein knock-down. The DBTC delivery system enables functional delivery of siRNA molecules selectively to liver cells including hepatocytes. Additionally, the Company has a platform of novel siRNA molecules based around its AtuRNAi chemical modification technology, which provides a number of advantages over conventional siRNA molecules. Silence's unique RNAi assets also include structural features for RNAi molecules and specific design rules for increased potency and reduced off-target effects of siRNA sequences.

The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and o
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Additional Listing
2. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
3. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
4. Silence Therapeutics Provides Corporate and Development Update
5. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
6. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
7. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
8. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
9. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
10. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
11. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... group leader Yung-Eun Sung has announced that they ... nitrogen-doped graphenes which can be applied as high ... Yung-Eun Sung is both a group leader at ... Basic Science* (IBS) and a professor at the ... significance with regards to the development of relative ...
(Date:7/24/2014)... prefer to settle into equilibriuma state of unchanging ... realm of non-equilibrium conditions where new possibilities lie. ... phases, such as temperature fluctuations, freezing and melting, ... their body temperature, airplanes to fly, and the ... But even though these conditions exist naturally and ...
(Date:7/24/2014)... Your cell phone may stay charged ... storage capacity. , New research indicates that lithium-ion ... at Lawrence Livermore National Laboratory and ... components will perform as electrodes. , The growing ... for higher-performance batteries. Several key characteristics of lithium-ion ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Three ... be semi-finalists in Livestrong’s Big C Competition. Out of ... are each headed to the semi-final round. In this ... exclusive three-month accelerator program, complete with mentoring from thought-leaders ... , As part of the angelMD commitment to the ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Getting More Life out of Lithium-ion Batteries 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... CONTINUE TO MANAGE ALS EAP IN ITALY AND ALL ... RESPONSIBILITY FOR REST OF WORLD , RICHMOND, Va., ... ), a biopharmaceutical company, today announced the signing of ... in the management of medicines on a named patient ...
... TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) ... the Southern District of New York dismissed proceedings filed ... ("Axonyx") against Axonyx and several of Axonyx,s former directors ... plaintiffs alleged that the defendants made misleading statements related ...
... Inverness Medical Innovations, Inc. (NYSE: IMA ), a ... health at home through the merger of rapid diagnostics and ... on its Series B Convertible Perpetual Preferred Stock (NYSE: IMA-PB). ... stock in an amount per share equal to the quotient ...
Cached Biology Technology:Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM) 2Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM) 3Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM) 4Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed 2
(Date:7/25/2014)... scientists from 25 countries and 35 states will ... the Genetics Society of America (GSA) next week ... conference will feature close to 500 presentations (including ... including gene expression and regulation, functional genomics, chemical ... and a variety of diseases. , Of ...
(Date:7/25/2014)... at the University of Adelaide has opened the way for ... powdery mildew. , In Australia, annual barley production is second ... mildew is one of the most important diseases of barley. ... discovered the composition of special growths on the cell walls ... into the leaf. , The research, by the ARC Centre ...
(Date:7/25/2014)... After development of diffusion tensor tractography (DTT), which ... reconstruction and estimation for three motor tracts, such ... the corticoreticular pathway became possible. The corticospinal tract ... for motor function in the human brain. Several ... tract by transtentorial herniation. In addition, some studies ...
Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2New hope for powdery mildew resistant barley 2
... Mich.---In cells, as in cities, disposing of garbage and ... service. In both city and cell, health problems can ... research by University of Michigan cell biologist Haoxing Xu ... garbage dump and recycling center, the lysosome, functions. These ...
... 14, 2010 The Institute for Clinical & Translational ... five years from the National Institutes of Health to ... for patients. UCI is the first medical research ... to receive the competitive Clinical & Translational Science ...
... (July 13, 2010) -- The 52nd meeting of ... convenes from July18 - 22, 2010 in Philadelphia, ... medical physics, a broadly-based scientific and professional discipline ... biology. Its membership includes medical physicists who specialize ...
Cached Biology News:Opening the gate to the cell's recycling center 2UCI receives prestigious federal research award to hasten medical advances 2Nanotech medicine, tumor tracking, new technologies and more 2Nanotech medicine, tumor tracking, new technologies and more 3Nanotech medicine, tumor tracking, new technologies and more 4Nanotech medicine, tumor tracking, new technologies and more 5Nanotech medicine, tumor tracking, new technologies and more 6Nanotech medicine, tumor tracking, new technologies and more 7Nanotech medicine, tumor tracking, new technologies and more 8Nanotech medicine, tumor tracking, new technologies and more 9Nanotech medicine, tumor tracking, new technologies and more 10Nanotech medicine, tumor tracking, new technologies and more 11Nanotech medicine, tumor tracking, new technologies and more 12Nanotech medicine, tumor tracking, new technologies and more 13Nanotech medicine, tumor tracking, new technologies and more 14Nanotech medicine, tumor tracking, new technologies and more 15Nanotech medicine, tumor tracking, new technologies and more 16Nanotech medicine, tumor tracking, new technologies and more 17
RORgamma (S-14)...
... Sophions newly introduced QPatch HT is taking ... more powerful level. With its ability to generate ... HT is enabling new screening paradigms in ion ... clamping with the same high quality afforded by ...
... aptamer screening and binding optimization and built ... on-chip synthesis platform. These microarrays are available ... Microarray Service. Probe Content ... than 1500 known aptamer sequences. Add up ...
... provides a comprehensive epitope analysis service ... on Paraflo microfluidic chips for immunological ... This comprehensive service includes assistance with ... sample(s) provided by you, single or ...
Biology Products: